SCHEMBL18607148

SCHEMBL18607148

COc1cc(F)c([N+](=O)[O-])cc1Nc1nccc(-c2cn(C)c3cc(C)sc23)n1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 2/20 0.46
MKNK1 Q9BUB5 1/20 0.46
EGFR P00533 14/20 0.43
IGF1R P08069 2/20 0.42
CDK2 P24941 2/20 0.42
DYRK1B Q9Y463 2/20 0.42
DYRK3 O43781 1/20 0.42
CLK1 P49759 1/20 0.42
CLK2 P49760 1/20 0.42
CDK5 Q00535 1/20 0.42
DYRK1A Q13627 1/20 0.42
CDK5R1 Q15078 1/20 0.42
DYRK2 Q92630 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
DYRK4 Q9NR20 1/20 0.42
CCNT1 O60563 2/20 0.40
CDK9 P50750 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18607064 0.86 EGFR (0.53) EGFR
SCHEMBL23729225 0.85 MKNK1 (0.52) MKNK2MKNK1EGFRIGF1RCDK2
SCHEMBL18606994 0.84 EGFR (0.54) MKNK2MKNK1EGFRIGF1RCDK2
SCHEMBL14660648 0.84 MKNK1 (0.65) MKNK2MKNK1EGFR
SCHEMBL32671769 0.84 MKNK1 (0.65) MKNK2MKNK1EGFR
SCHEMBL29555980 0.84 MKNK1 (0.65) MKNK2MKNK1EGFR
Hydrochloric Acid SCHEMBL31218386 0.84 MKNK1 (0.64) MKNK2MKNK1EGFR
SCHEMBL28380189 0.84 MKNK1 (0.53) MKNK2MKNK1EGFRIGF1RCDK2
SCHEMBL28620389 0.84 EGFR (0.56) MKNK2MKNK1EGFRIGF1RCDK2
SCHEMBL17683272 0.82 MKNK1 (0.51) MKNK2MKNK1EGFRIGF1RCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10377747-B2 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2019-08-13 US disclosed
US-10377747-B2 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2019-08-13 US disclosed
US-20180208585-A1 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2018-07-26 US disclosed
US-20180208585-A1 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2018-07-26 US disclosed
EP-3345906-A1 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF Wuxi Shuangliang Biotechnology Co., Ltd. (CN) 2018-07-11 EP disclosed
WO-2017035753-A1 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF 无锡双良生物科技有限公司 2017-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208585-A1 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF ERBB2, EGFR, ERBB3 MKNK2 1885/4885MKNK1 2782/4885EGFR 2/4885
US-10377747-B2 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof ERBB2, EGFR, ERBB3 MKNK2 1906/4885MKNK1 2618/4885EGFR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.